Mesa Laboratories 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Second-quarter organic revenue grew 2.6%, compared with 1% in the first quarter; first-half organic revenue growth was 1.8%.
- Excluding clinical genomics, revenue grew about 5% in the quarter and about 3% in the first half.
- SDC revenue grew 14.6% organically in the second quarter and about 5% in the first half; trailing 12-month revenue was $103.9 million, up 8.5%.
- Calibration Solutions grew about 3.5% organically, while Biopharmaceutical Development revenue declined 8.2% organically and Clinical Genomics revenue declined 8.8%.
- Gross profit was $39.9 million, or 64% of revenue, compared with 61.5% a year ago; operating expenses declined 3.4% to $31.5 million.
- GAAP operating income increased 77.6% to $8.4 million, net income was $4.3 million or $0.75 per diluted share, and adjusted EBITDA increased 21.1% to $17.3 million, or 27.8% of revenue.
- First-half operating cash flow was $18.8 million, and the company repaid $20.1 million of debt net; quarter-end cash was $22.3 million, with $57.8 million available under the revolver.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to the Mesa Labs Second Quarter 2027 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Doug Farrell, Investor Relations. Doug, please go ahead. Thank you, operator.
Joining me on the call today is Mesa CEO, Siddhartha Kadia, and CFO, John Sakys. Please be advised that our remarks today, including answers to your questions, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements include those relating to future financial and operational results, future taxes, future strategic and operational initiatives, new products, and our future Total Net Leverage Ratio. Words such as seek, expect, plan, intend, anticipate, believe, could, should, estimate, may, target, project, and similar expressions may also identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to be materially different from those currently anticipated.
Those include risks relating to market acceptance of and demand for our products, our ability to execute on strategic, commercial, and operational initiatives, and achieve the anticipated benefits from those initiatives, potential issues relating to our manufacturing, fulfillment, supply chain performance, possible changes in customer purchasing patterns, the development and success of new products and product launches, regulatory matters, the effect on our business of capital allocation decisions and debt reduction initiatives, expected tax rates, national and global economic conditions, our ability to achieve our fiscal 2027 guidance, the timing, cost, and benefits of the savings plan and restructuring program, potential impairment charges, share repurchases, and other factors described in our filings within the Securities and Exchange Commission, which are incorporated by reference. We disclaim any obligation to update these forward-looking statements.
In addition, we will provide certain non-GAAP financial information on this call, including adjusted EBITDA, adjusted operating income, organic and constant currency organic revenue growth, revenues excluding Clinical Genomics, and combined gross profit for our Quality Control and Life Sciences Tools businesses, each for the quarter and, where noted, on a year-to-date or trailing 12-month basis. The relevant definitions and reconciliations to the most directly comparable GAAP measures may be found in our earnings release and in the supplemental reconciliation posted in the investor relations section of our website at mesalabs.com. With that, let me turn the call over to Siddhartha.
Thank you, and good afternoon, everyone. in August, I told you I would use every one of these calls the same way, to be direct about what's working, what is not yet working, and what we have decided to do about it. That has not changed. I also told you that August was the appetizer and that the dinner would come in November, full-year guidance alongside our first-half results. This is that call. Before anything else, let me read back what we said we would do, because I think consistency is the first thing you should be able to hold us to. We said I would give you a clear read on the durable fix in SDC. I'll give you that read in a moment, and it's a mixed one, which is why I want to be precise about it.
We said the next Gyrolab platform will launch in fiscal 2028. That is still the plan. We said Clinical Genomics was being managed deliberately and that we would have more to share as that work progressed. On October 13, we announced how we are changing the way we manage that business for profitability. We said we would keep strengthening the balance sheet towards 1.5 to 1.75 turns of net leverage by the end of the fiscal year. We are at 1.75 times already within that range with two quarters to go, down from 1.85 at the end of June. I said acquisitions were not my near-term priority and that I would come back to capital allocation today. I will. And we said we would give you full-year guidance on this call.
We are doing that today, and you will see that it shows real and growing earnings power. So, a quarter of real progress, one franchise that had a disappointing quarter for reasons I'll explain, the decisions we made in October, and our first full-year guidance. Let me take you through it. Before I do, one welcome. Sanket Shah joined Mesa on November 2 as our General Counsel, as we announced today. He strengthens the leadership team we are building, and I'm glad to have him with us. Next, I have four core messages for you. If you take four things away from this call, let it be this. First, growth is building, led by our two steadiest franchises. Organic revenues grew 2.6% in the second quarter, up from 1% in the first.
Excluding Clinical Genomics, which we are reshaping, revenues grew about 5% in the quarter and about 3% in the first half. Sterilization and Disinfection Control grew in the mid-teens organically, and Calibration Solutions grew in the low single digits. The two franchises doing what they are built to do. Biopharmaceutical Development had a weak quarter for reasons that are about timing rather than demand, and I'll be specific about them. Revenues will move between quarters in a business like ours. What I want you to watch is the direction, and the direction is up. For the full year, we expect adjusted EBITDA to grow faster than revenues. Second, we acted on Clinical Genomics, and we are reinvesting where the returns are. On October 13, we announced a savings plan that is expected to reduce our annualized operating costs by approximately $9.3 million.
We are reinvesting approximately $4.3 million of those savings, primarily in commercial capacities in the businesses and regions where we see the most opportunity for profitable growth, and in key corporate positions. Our total expected net annualized cost reduction is approximately $5 million. Clinical Genomics is now being managed for profitability, not for scale. Third, a capital allocation strategy agreed with the board that starts with the balance sheet. Our capital allocation started in October when we moved capital out of Clinical Genomics and into our more profitable businesses, and that work continues because every business competes for capital on the returns it earns. Together with the board, we have now completed a review of our capital allocation strategy, and the priorities are simple. We invest in our own businesses where we see the best returns for profitable growth. We keep the balance sheet strong.
We repaid $20.1 million of debt in the first half, and our net leverage is 1.75 times. As we earn it, we will bring distributors in-house and then add small tuck-ins in our Quality Control businesses. Alongside those priorities, the board has authorized a share repurchase program of up to $40 million through December 2028, which gives us the flexibility to repurchase shares opportunistically while we continue to reduce debt. Fourth, our first full-year guidance. Today, we are giving full-year guidance for the first time, revenues and adjusted EBITDA. I built it the way I told you I would, on a first half year of data under the operating changes we made, and conservatively, because a number you can count on is worth more than a number that flatters a quarter. In the first half, adjusted EBITDA grew 20.9% on revenues, up about 1.8%.
For the full year, our guidance has it growing 5%-8%, even after the reinvestment and lower Clinical Genomics revenues. Next, let me address Sterilization and Disinfection Control, the read that I promised. Let me start where I spent the most time in August. I told you SDC had a delivery reliability problem, not a demand problem, and that I would give you a clear read on the durable fix in November. Here it is. First, the results. SDC grew 14.6% organically in the second quarter. I want to be precise about what that number is. Most of it is comparison. Delivery delays caused past-due backlog to build in the second quarter last year. During the second quarter of this year, past-due backlog remained roughly steady and at a substantially lower level than a year ago.
For the trailing 12 months, SDC revenues were $103.9 million, up 8.5%, the highest 12 months in this franchise's history. On a first-half basis, SDC grew about 5%. Those are the right lenses for this franchise. Second, the fix. In August, I said the job was converting surge work into standard work. On most of our product lines, we've done that. The manufacturing issues behind the delays have been resolved, and those lines are now shipping on a schedule our customers can plan around. That is real, and it's our team's work. In September, the FDA inspected our Bozeman facility, where we make biological indicators, and issued no observations. I promised you a clear read, not a victory lap. Here is the part that is not finished.
One key product line, the one that carried the largest share of our past-due backlog, has only been partially resolved. We understand the problem, we have the right people working on it, and it remains the single biggest priority in this business. Until it is fixed, SDC will not be as reliable as it should be, and I will not tell you it is. The honest truth is this, the durable fix is in place for most of the franchise. It is not yet in the place for all of it, and demand has been there throughout. Our customers have continued to order from us, and as product has become available, it has moved. That tells you what this franchise is worth once delivery is fully reliable. Next, Calibration Solutions. That business grew about 3.5% organically, on top of nearly 11% growth a year ago.
Calibration Solutions is a recurring service-driven business that compounds quietly, and it did that again this quarter. We are adding business development capacity here as part of the reinvestment I described to expand the geographic reach of this business. Now, onto Biopharmaceutical Development. Biopharmaceutical Development had a weak quarter. Revenues declined 8.2% organically, and I want to tell you exactly why, because the reasons are not a lack of demand. The first reason is export controls. As I said in August, export control processing on certain in-hand orders has been taking longer than we expected, and delays have continued through the second quarter. The second reason is simpler and more disappointing. A number of shipments missed our second quarter close by a few days. Those orders were in hand and shipped by mid-October, so they will be third quarter revenues. I won't pretend that's a good quarter. It is not. But it's a quarter where revenues moved from one period to the next, not one where the customers walked away.
The commercial rebuild around our general manager is continuing. The Gyrolab next-generation platform remains on track to launch in fiscal 2028, and I continue to expect this business to grow for the full year. Finally, Clinical Genomics, what we announced on October 13th. In August, I said we are managing Clinical Genomics deliberately with full attention to its cost structure and returns, and that we have more to share as that work progressed. On October 13th, we shared our restructuring and savings plan. Clinical Genomics revenues declined 8.8% in the quarter, mainly from the timing of consumables orders from a large customer, with China modestly lower. But over several years, the pattern has been one of declining revenues, and that is the reason we decided to restructure the business.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
